Affitech renews exclusive worldwide phage display license from DKFZ
"Breitling" patents hold key position in human antibody discovery field
The renewed terms provide Affitech the worldwide exclusive license until the expiry of the patents in the respective territories, and include the capability of Affitech to sublicense the IP to any company or organization worldwide. No other terms of the agreement were disclosed.
The DKFZ agreement represents another milestone as Affitech continues to progress towards becoming a product-focused human antibody therapeutics company. Several of its in-house discovered antibodies generated by its pioneering CBAS(TM) (Cell Based Antibody Selection) technology are currently undergoing pre-clinical development.
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous